AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca ultomiris (ravulizumab) — US product sales ($M) ($M)
Form 6-K / 20-F Product Sales Table
Latest, FY2025
2,667
Period ended Dec 31, 2025
Change on a year earlier
+18.0%
2,261 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultomiris (ravulizumab) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,667 | +18.0% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 2,261 | +29.2% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,750 | +54.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,136 | +198.2% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 381 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up ultomiris (ravulizumab) — us product sales ($m)
Cite this data
StockData. (2026). AstraZeneca Ultomiris (ravulizumab) — US product sales ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_ultomiris_us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.